Skip to main content

Table 2 Showing the role of HSCT and BMT in AIH

From: Stem cell therapies for autoimmune hepatitis

  Patient main disorder Patient gender Donor Transplanted cells Results Ref.
HSCT patient with SCD and AIH Female Patient’s HbSA haploidentical father HSCT - After HSCT by 2 years, the data showed a full donor hematopoiesis, no SCD manifestation was noted, cerebral vasculopathy appeared to be resolved and the patient required no additional medical treatment. Antinuclear and anti-smooth muscle autoantibodies were negative 2 months after HSCT, and there was no recurrence of AIH in the patient. [89]
BMT Patient with a 4-year history of AIH and developed acute AL-L2. Male His healthy 25-year-old sibling was chosen as an MLC-non-reactive BM donor who was HLA A-, HLA B-, and DR-matched - 6·8 × 108 bone marrow cells for each kilogram (overall 4·7 × 1010 cells)
- 105 T lymphocytes for each kilogram body from a donor's peripheral blood (overall of 69 × 105 T lymphocytes)
- Allogeneic transplantation of BM and donor T cells resulted in the normalization of T-cell responses to ASGPR, the elimination of antibodies to the same autoantigen, and the noticeable treatment of AIH. [90]
  1. AIH autoimmune hepatitis, SCD sickle cell disease, TCRαβ T cell receptor, PBSC peripheral blood stem cell, HSCT hematopoietic stem cell transplantation, GvHD graft-versus-host disease, AL-L2 acute lymphoblastic leukemia, HLA human leukocyte antigen, MLC mixed leukocytes culture, BMT bone marrow transplantation, ASGPR antiasialoglycoprotein receptor